https://www.live-feeds.com/feed/the-weight-i-lost-with-glp-1s-came-back-with-taxesContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/the-weight-i-lost-with-glp-1s-came-back-with-taxeshttps://www.live-feeds.com/feed/the-weight-i-lost-with-glp-1s-came-back-with-taxes#u69978Wed, 16 Sep 2026 07:45:42 +0000Recent analyses show that most weight lost on GLP-1 obesity drugs comes from fat, while relative muscle mass is largely preserved. However, patients who stop taking medications like semaglutide and tirzepatide face rapid weight regain that can exceed initial losses, triggering mental health challenges such as depression. Meanwhile, doctors and loved ones note that some ideal candidates refuse to take these popular weight-loss drugs. Runners using GLP-1s also face specific concerns regarding bone and tendon injury risks, requiring adjustments to fueling, mileage, and strength training to protec https://www.live-feeds.com/feed/the-weight-i-lost-with-glp-1s-came-back-with-taxeshttps://www.live-feeds.com/feed/the-weight-i-lost-with-glp-1s-came-back-with-taxes#u68856Tue, 15 Sep 2026 10:25:14 +0000Recent analyses show that patients who stop taking GLP-1 medications like semaglutide and tirzepatide experience rapid weight regain. Reports indicate that the lost pounds often return quickly, sometimes exceeding initial losses. This rapid regain cycle also triggers mental health concerns, including depression among patients dealing with weight return. Medical models and major analyses are mapping out the specific weight regain curve to better understand long-term planning for obesity treatments. Understanding these post-treatment trajectories helps clinicians address both the physical and ps